drugset / Trial / NCT01204710
A Study of Olaratumab (IMC-3G3) in Prostate Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a study evaluating the safety and efficacy of the monoclonal antibody olaratumab plus mitoxantrone plus prednisone compared to mitoxantrone plus prednisone in metastatic castration-refractory prostate cancer following disease progression or intolerance on docetaxel-based chemotherapy.
Timeline
- Start
- 2010-10
- Primary completion
- 2012-09
- Completion
- 2013-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Olaratumab | Monoclonal antibody | 15 mg/kg | Intravenous |
| Background | 5 mg orally (PO) twice daily (BID) on each day | Unknown | 5 mg | Oral |
| Background | Mitoxantrone | Small molecule | 12 mg/m2 | Intravenous |